Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to validate it

Ongoing clinical studies provide samples to the HBI's Drug Discovery Platform to validate biosynthetic NGB composition and indicate which donor's microbiome-derived components need to be isolated to create final NGB. The company announces that their proof-of-concept fecal microbiome products decolonize over 70% of ARB, and this is a great base to assume that synthetic microbiome will do the same or even better. Ongoing clinical studies provide samples to the HBI's Drug Discovery Platform to...

Ongoing clinical studies provide samples to the HBI's Drug Discovery Platform to validate biosynthetic NGB composition and indicate which donor's microbiome-derived components need to be isolated to create final NGB. The company announces that their proof-of-concept fecal microbiome products decolonize over 70% of ARB, and this is a great base to assume that synthetic microbiome will do the same or even better.

Human Biome has built a Drug Discovery Platform that includes a microbiota facility, Clinical Platform to perform contextual FMT studies, BioBank with over 3,000 clinical samples collected to date, and finally deep-tech-packed MicroDrug Platform to predict compositions and synthesize the NGBs – added dr Bilinski.

About Human Biome

HB is a "second-generation microbiome company" developing donor-independent synthetic microbiomes, as NGBs.

The "second-generation" because we knew from the very beginning that composing real synthetic microbiome drug is a big deal. This is why we made very rich and viable, anaerobic, donor-derived fecal microbiota preparations for proof-of-concept studies only. Spending money for registering FMT, from a business point of view, is unprofitable. Our aim was to bring together cutting-edge science to develop an artificial microbiota synthesis technology and create fully synthetic, context-based microbiota to overcome biggest challenges in medicine – summarizes dr Bilinski.

Company launches Series A Funding to build deep-tech culturomic-genomic "QLab" and synthesize NGB.

Contact: Human Biome, investors@human-biome.com, +48 884 299 668 www.human-biome.com

View original content:https://www.prnewswire.co.uk/news-releases/human-biome-announces-prediction-of-first-in-class-biosynthetic-microbiome-against-silent-pandemic-of-antibiotic-resistant-bacteria-and-doses-first-patients-in-contextual-fmt-study-to-validate-it-301971976.html